PMID- 15701467
OWN - NLM
STAT- MEDLINE
DCOM- 20050607
LR  - 20220311
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 7
IP  - 2
DP  - 2005 Mar 2
TI  - The significance of CA125 levels in patients with chronic congestive heart 
      failure. Correlation with clinical and echocardiographic parameters.
PG  - 199-203
AB  - OBJECTIVE: To assess serum levels of carbohydrate antigen 125 (CA125) in patients 
      with chronic congestive heart failure (CHF) and to assess any correlation with 
      clinical symptoms and echocardiographic indices. PATIENTS AND METHODS: We 
      enrolled 77 male patients (mean age: 73+/-10 years) admitted to the Cardiology 
      Emergency Department (ED) with cardiac symptoms requiring hospitalization. 
      Diagnosis of CHF was based upon medical history or initial echocardiographic 
      evaluation on current admission. Serum CA125 was measured by an enzyme 
      immunoradiometric assay, on admission and before discharge. RESULTS: The median 
      overall CA125 value was 22.4 (11.5-48.9) U/ml. Serum CA125 levels were related to 
      the severity of CHF [New York Heart Association (NYHA) class I: 19.2 (7.2-31) 
      U/ml, NYHA class II: 17.6 (10-23) U/ml, NYHA class III: 32 (25-77) U/ml and NYHA 
      class IV: 34.3 (18.6-77) U/ml (p<0.04)]. Patients in NYHA classes III and IV had 
      significantly higher mean values of CA125, than patients in class II (p<0.005 and 
      p<0.05, respectively). Moreover, patients with fluid congestion (pulmonary 
      congestion, ankle edema) had higher levels of serum CA125 than patients without 
      congestion (p=0.002 and p<0.03, respectively). Finally, levels of serum CA125 
      correlated weakly with right ventricular systolic pressure (RVSP) and renal 
      function, while no significant correlation was found between CA125 and E wave 
      deceleration time on Doppler echocardiography, left ventricular ejection fraction 
      (LVEF), left ventricular end-diastolic diameter (LVEDD), liver function and the 
      medical treatment prescribed. CONCLUSION: Serum CA125 is associated with the 
      clinical severity of CHF and the symptoms and signs of fluid congestion and 
      therefore may be a useful additional tool for the evaluation and clinical staging 
      of these patients.
FAU - Kouris, Nikos T
AU  - Kouris NT
AD  - Cardiology Department, Western Attica General Hospital, Athens, Greece. 
      nikoskou@otenet.gr
FAU - Zacharos, Ioannis D
AU  - Zacharos ID
FAU - Kontogianni, Dimitra D
AU  - Kontogianni DD
FAU - Goranitou, Georgia S
AU  - Goranitou GS
FAU - Sifaki, Maria D
AU  - Sifaki MD
FAU - Grassos, Haris E
AU  - Grassos HE
FAU - Kalkandi, Eleni M
AU  - Kalkandi EM
FAU - Babalis, Dimitris K
AU  - Babalis DK
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (CA-125 Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - CA-125 Antigen/*blood
MH  - Cohort Studies
MH  - Heart Failure/*blood/diagnostic imaging/physiopathology
MH  - Heart Ventricles/diagnostic imaging
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Stroke Volume/physiology
MH  - Ultrasonography
MH  - Ventricular Pressure/physiology
EDAT- 2005/02/11 09:00
MHDA- 2005/06/09 09:00
CRDT- 2005/02/11 09:00
PHST- 2003/07/29 00:00 [received]
PHST- 2003/12/16 00:00 [revised]
PHST- 2004/07/05 00:00 [accepted]
PHST- 2005/02/11 09:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2005/02/11 09:00 [entrez]
AID - S1388-9842(04)00230-2 [pii]
AID - 10.1016/j.ejheart.2004.07.015 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2005 Mar 2;7(2):199-203. doi: 10.1016/j.ejheart.2004.07.015.